← Leaderboards
John M Porter
Oregon Health And Science University
$1,379,288
Attributed
$1,379,288
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,379,288 · 4
By mechanism
M01$1,379,288 · 4
Top collaborators
No co-investigators on record.
Most similar at Oregon Health And Science University
Same institution · by research overlap
- Richard L Stouffer$23,398,962
- Alfred J Lewy$10,657,131
- Edwin W. Mc Cleskey$3,191,094
- Lloyd M Taylor$1,932,600
- Alfred L Nuttall$23,220,220
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationIntravenous AdministrationDrug Screening /EvaluationGaitCardiovascular Disorder ChemotherapyClaudicationPainVasodilatationAmputationArtery OcclusionDosageIloprostIschemiaLimbsOral AdministrationPlatelet Aggregation InhibitorsProstacyclinsProstaglandin FUlcerAcute Disease /DisorderNutrient Intake ActivitySmoking
Grant awards (16)
INTRAVENOUS AS 013 FOR TREATMENT OF SEVERE LIMB ISCHEMIA$172,411
M01 · FY2002 · RR
INTRAVENOUS AS 013 FOR TREATMENT OF SEVERE LIMB ISCHEMIA$172,411
M01 · FY2002 · RR
DOSE RESPONSE EVALUATION OF ILOPROST IN TREATMENT OF CLAUDICATION$172,411
M01 · FY2002 · RR
DOSE RESPONSE EVALUATION OF ILOPROST IN TREATMENT OF CLAUDICATION$172,411
M01 · FY2002 · RR
Variability of treadmill walking in claudicants$172,411
M01 · FY2001 · RR
Efficacy of avasimibe in peripheral arterial disease$172,411
M01 · FY2001 · RR
DOSE RESPONSE EVALUATION OF ILOPROST IN TREATMENT OF CLAUDICATION$172,411
M01 · FY2001 · RR
INTRAVENOUS AS 013 FOR TREATMENT OF SEVERE LIMB ISCHEMIA$172,411
M01 · FY2001 · RR
INTRAVENOUS AS 013 FOR TREATMENT OF SEVERE LIMB ISCHEMIA$0
M01 · FY2001 · RR
Variability of treadmill walking in claudicants$0
M01 · FY2001 · RR
DOSE RESPONSE EVALUATION OF ILOPROST IN TREATMENT OF CLAUDICATION$0
M01 · FY2001 · RR
Efficacy of avasimibe in peripheral arterial disease$0
M01 · FY2001 · RR
Efficacy of avasimibe in peripheral arterial disease$0
M01 · FY2000 · RR
INTRAVENOUS AS 013 FOR TREATMENT OF SEVERE LIMB ISCHEMIA$0
M01 · FY2000 · RR
Variability of treadmill walking in claudicants$0
M01 · FY2000 · RR
DOSE RESPONSE EVALUATION OF ILOPROST IN TREATMENT OF CLAUDICATION$0
M01 · FY2000 · RR